SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Nijenhuis CM, ter Horst PGJ, de Jong-van den Berg LTW, Wilffert B. Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 1: literature review. Br J Clin Pharmacol 2012; 73: 1626.
  • 2
    Nijenhuis CM, ter Horst PGJ, van Rein N, Wilffert B, de Jong-van den Berg LTW. Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 2: testing the hypotheses. Br J Clin Pharmacol 2012; 73: 12634.
  • 3
    Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358: 25260.
  • 4
    Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5: 2608.
  • 5
    Warren JB. The regulatory process: pharmacovigilance in practice. In: The Law and Regulation of Medicines, ed. Feldschreiber P. Oxford: Oxford University Press, 2008; 12963.
  • 6
    International Conference on Harmonisation of Technical requirements for Registration of Pharmaceuticals for Human Use ICH Harmonised Tripartite Guideline the Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-term Treatment of Non-life-threatening Conditions E1. 1995. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E1/Step4/E1_Guideline.pdf (last accessed 9 September 2011).
  • 7
    Dewar HA, Oliver MF. Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials. BMJ 1971; 4: 7846.
  • 8
    Committee of Principal Investigators. WHO cooperative trial on prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet 1984; 2: 6004.
  • 9
    Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, Wiebe S, Thurman D, Koppel BS, Kaplan PW, Robinson JN, Hopp J, Ting TY, Gidal B, Hovinga CA, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Hirtz D, Le Guen C. Practice parameter update: management issues for women with epilepsy. Focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes. Neurology 2009; 73: 13341.
  • 10
    Crockett MJ, Clark L, Tabibnia G, Lieberman MD, Robbins TW. Serotonin modulates behavioral reactions to unfairness. Science 2008; 320: 1739.
  • 11
    Warren J. Scientific and socio-economic impact of serotonin's discovery. In: Memory of Vittorio Erspamer, eds Negri L, Melchiorri P, Hökfelt T, Nisticò G. Rome: Exorma, 2009; 6472.
  • 12
    March JS, Vitiello B. Benefits exceed risks of newer antidepressant medications in youth – maybe. Clin Pharmacol Ther 2009; 86: 3557.
  • 13
    Potter WZ. Benefits exceed risks of newer antidepressant medication in youth – maybe not. Clin Pharmacol Ther 2009; 86: 3579.